Penclomedine (NSC-338720) is a novel cytotoxic agent which has shown activity in several
tumor model systems when screened as an aqueous suspension by National Cancer …

Abstract Penclomedine (NSC-338720) is a low melting point, poorly water-soluble cytotoxic
agent with good solubility in triglycerides and a high octanol/water partition coefficient. Its …

Penclomedine, a highly substituted pyridine derivative, has been selected by the National
Cancer Institute for evaluation as a potential anticancer agent based on antitumor activity …

PURPOSE A novel phase I trial design was used to determine the maximum-tolerated dose
(MTD) and pharmacokinetics for penclomedine when administered as an intravenous (iv) …

PURPOSE To determine the maximum-tolerated dose (MTD), principal toxicities, and
pharmacologic behavior of penclomedine, a novel alkylating agent. PATIENTS AND …

Analogues of penclomedine (PEN, 3, 5-dichloro-4, 6-dimethoxy-2-(trichloromethyl) pyridine)
and its metabolites have been synthesized and evaluated as potential antitumor agents …

Purpose The purpose of this investigation was to synthesize a series of carbonate and
carbamate derivatives of 4-demethylpenclomedine (DM-PEN), the major plasma non-toxic …

Purpose: The purpose of this investigation was to synthesize a series of thiolo-, thiono-and
dithiocarbonate and thiocarbamate derivatives of 4-demethylpenclomedine (DM-PEN), the …

Penclomedine, a lipophilic alpha-picoline derivative, is undergoing clinical development
presently because of its pronounced antitumor activity against intracerebral (ic) tumor …

Abstract Penclomedine [3, 5-dichloro-4, 6-dimethoxy-2-(trichloromethyl) pyridine], an
antitumor agent, is currently in Phase I clinical trials and is believed to be a prodrug. In these …